Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies show ...
Study in a TSC mouse model further demonstrates simufilam’s anti-seizure activity Study conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout model First clinical study for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback